4//SEC Filing
Ainsworth Sean 4
Accession 0001596771-20-000111
CIK 0001228627other
Filed
Nov 8, 7:00 PM ET
Accepted
Nov 9, 6:08 PM ET
Size
10.0 KB
Accession
0001596771-20-000111
Insider Transaction Report
Form 4
Ainsworth Sean
Director
Transactions
- Award
Common Stock
2020-11-05+35,800→ 35,800 total - Award
Stock Option (right to buy)
2020-11-05+52,825→ 52,825 totalExercise: $1.21Exp: 2029-12-27→ Common Stock (52,825 underlying) - Award
Stock Option (right to buy)
2020-11-05+35,663→ 35,663 totalExercise: $0.90Exp: 2028-10-01→ Common Stock (35,663 underlying)
Footnotes (3)
- [F1]The reporting person acquired the shares and options to acquire shares of the common stock of Rexahn Pharmaceuticals, Inc. ("Rexahn") on November 5, 2020, in exchange for shares and options to acquire shares of the common stock of Ocuphire Pharma, Inc. ("Ocuphire"), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of June 17, 2020, as amended, between Rexahn, Razor Merger Sub, Inc., and Ocuphire pursuant to which Ocuphire became a wholly-owned subsidiary of Rexahn. Per the terms of the Merger Agreement, each share of Ocuphire common stock was converted into the right to receive 1.0565 shares of Rexahn common stock. Subsequent to the merger, the name of the issuer was changed from Rexahn Pharmaceuticals, Inc. to Ocuphire Pharma, Inc.
- [F2]The option is fully vested.
- [F3]5,282 shares vested on December 31, 2019, and the remaining shares vest in equal monthly installments from January 2020 through December 2022 subject to continued service.
Documents
Issuer
Ocuphire Pharma, Inc.
CIK 0001228627
Entity typeother
Related Parties
1- filerCIK 0001830296
Filing Metadata
- Form type
- 4
- Filed
- Nov 8, 7:00 PM ET
- Accepted
- Nov 9, 6:08 PM ET
- Size
- 10.0 KB